Trials / Completed
CompletedNCT05952089
A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
An Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of Danicamtiv on the Pharmacokinetics of Midazolam in Patients With Stable Heart Failure With Reduced Ejection Fraction
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is assess the effect of danicamtiv, as an inducer on the drug levels of midazolam in participants with heart failure with reduced ejection fraction (HFrEF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Danicamtiv | Specified dose on specified days |
| DRUG | Midazolam | Specified dose on specified days |
Timeline
- Start date
- 2023-08-17
- Primary completion
- 2024-03-15
- Completion
- 2024-03-19
- First posted
- 2023-07-19
- Last updated
- 2024-04-04
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05952089. Inclusion in this directory is not an endorsement.